Contribution of dietary advanced glycation end products (AGE) to circulating AGE: Role of dietary fat

British Journal of Nutrition

Volumn 114, Issue 11, 2015, Pages 1797-1806

  Davis, Kathleen E ^a   Prasad, Chandan ^b   Vijayagopal, Parakat ^b   Juma, Shanil ^b   Adams Huet, Beverley ^a   Imrhan, Victorine ^b  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^b TEXAS WOMAN'S UNIVERSITY   (United States)

Author keywords

Advanced glycation end products; Glycotoxins; High fat diet; Inflammation; Low fat diet; Maillard reaction products; Obesity

Indexed keywords

ADIPONECTIN; ADVANCED GLYCATION END PRODUCT; ADVANCED GLYCATION END PRODUCT RECEPTOR; C REACTIVE PROTEIN; BIOLOGICAL MARKER; FAT INTAKE; LYSINE; N(6)-CARBOXYMETHYLLYSINE; SRAGE PROTEIN, HUMAN;

ADULT; ANALYTIC METHOD; ARTICLE; BIOELECTRICAL IMPEDANCE ANALYSIS; BIOENERGY; CLINICAL PROTOCOL; CONTROLLED STUDY; COOKING; CROSSOVER PROCEDURE; CYTOKINE PRODUCTION; DIETARY INTAKE; FAT INTAKE; FEMALE; FOOD ANALYSIS; GLYCATION; HUMAN; HUMAN EXPERIMENT; LIPID DIET; LOW FAT DIET; MALE; NORMAL HUMAN; OXIDATIVE STRESS; PILOT STUDY; PROTEIN ANALYSIS; PROTEIN BLOOD LEVEL; PROTEIN CONTENT; PROTEIN FUNCTION; PROTEIN GLYCOSYLATION; UPREGULATION; WAIST CIRCUMFERENCE; ADVERSE EFFECTS; ANALOGS AND DERIVATIVES; BLOOD; BODY MASS; CLINICAL TRIAL; MEAL; METABOLISM; MIDDLE AGED; OBESITY; POSTPRANDIAL STATE; RANDOMIZED CONTROLLED TRIAL; WESTERN DIET; YOUNG ADULT;

ADULT; ADVANCED GLYCOSYLATION END PRODUCT-SPECIFIC RECEPTOR; BIOMARKERS; BODY MASS INDEX; BREAKFAST; CROSS-OVER STUDIES; DIET, WESTERN; DIETARY FATS; FEMALE; GLYCOSYLATION END PRODUCTS, ADVANCED; HUMANS; LYSINE; MAILLARD REACTION; MALE; MIDDLE AGED; OVERWEIGHT; PILOT PROJECTS; POSTPRANDIAL PERIOD; YOUNG ADULT;

EID: 84949323103     PISSN: 00071145     EISSN: 14752662     Source Type: Journal    
DOI: 10.1017/S0007114515003487     Document Type: Article

References (59)

1. Cordain L, Eaton SB, Sebastian A, et al. (2005) Origins and evolution of the Western diet: health implications for the 21st century. Am J Clin Nutr 81, 341-354.
2. Kalousova M, Zima T, Tesar V, et al. (2005) Advanced glycooxidation end products in chronic disease-clinical chemistry and genetic background. Mutat Res 579, 37-46.
3. Vlassara H & Striker GE (2011) AGE restriction in diabetes mellitus: A paradigm shift. Nat Rev Endocrinol 7, 426-539.
4. Semba RD, Nicklett EJ & Ferrucci L (2010) Does accumulation of advanced glycation end products contribute to the aging phenotype? J Gerontol A Biol Sci Med 65, 963-975.
5. Barlovic DP, Soro-Paavonen A & Jandeleit-Dahm KA (2011) RAGE biology, atherosclerosis and diabetes. Clin Sci 121, 43-55.
6. Cai W, He J-C, Zhu L, et al. (2008) Oral glycotoxins determine the effects of calorie restriction on oxidant stress, age-related diseases, and lifespan. Am J Pathology 173, 327-336.
7. Brownlee M (2001) Biochemistry and molecular cell biology of diabetic complications. Nature 414, 813-820.
8. Requena JR, Ahmed MU, Fountain CW, et al. (1997) Carboxyethylethanolamine, a biomarker of phospholipids modification during the Maillard reaction in vivo. J Biol Chem 272, 17453-17479.
9. Sgarbieri VC, Amaya J, Tanaka M, et al. (1973) Nutritional consequences of the Maillard reaction: amino acid availability from fructose-lysine and fructose-tryptophan in the rat. J Nutr 103, 657-663.
10. Koschinsky T, He C-J, Mitsuhashi T, et al. (1997) Orally absorbed reactive glycation products (glycotoxins): an environmental risk factor in diabetic nephropathy. Proc Natl Acad Sci 94, 6474-6479.
11. Raucci A, Cugusi S, Antonelli A, et al. (2008) A soluble form of the receptor for advanced glycation endproducts (RAGE) is produced by proteolytic cleavage of the membrane-bound form by the sheddase a disintegrin and metalloprotease 10 (ADAM10). FASEB J 22, 3716-3727.
12. Kalea AZ, Schmidt AM & Hudson BI (2011) Alternative splicing of RAGE: roles in biology and disease. Front Biosci 16, 2756-2770.
13. Hull GL, Woodside JV, Ames J, et al. (2012) N-carboxymethyl lysine content of foods commonly consumed in a Westernstyle diet. Food Chem 131, 170-174.
14. Uribarri J, Woodruff S, Goodman S, et al. (2010) Advanced glycation end products in foods and a practical guide to their reduction in the diet. J Am Diet Assoc 110, 911-916.
15. Delgado-Andrade C, Seiquer I, Haro A, et al. (2010) Development of the Maillard reaction in foods cooked by different techniques: intake of Maillard-derived compounds. Food Chem 122, 145-153.
16. Srey C, Hull GLJ, Connolly L, et al. (2010) Effect of inhibitor compounds on n-epsilon-carboxymethyllysine and n-epsilon carboxyethyllysine formation in model foods. J Agric Food Chem 58, 12036-12041.
17. Delgado-Andrade C, Seiquer I, Navarro MP, et al. (2007) Maillard reaction indicators in diets usually consumed by the adolescent population. Mol Nutr Food Res 51, 341-351.
18. Goldberg T, Weijing C, Peppa M, et al. (2004) Advanced glycoxidation end products in commonly consumed foods. J Am Diet Assoc 104, 1287-1291.
19. Poulsen MW, Hedegaard RV, Andersen JM, et al. (2013) Advanced glycation endproducts in food and their effects on health. Food and Chem Toxicol 60, 10-37.
20. Uribarri J, Cai W, Sandu O, et al. (2005) Diet-derived advanced glycation end products are major contributors to the body's AGE pool and induce inflammation in healthy subjects. Ann N Y Acad Sci 103, 461-466.
21. Ames JM (2007) Evidence against dietary advanced glycation endproducts being a risk to human health. Mol Nutr Food Res 51, 1085-1090.
22. Drusch S, Faist V, Erbersdobler HF, et al. (1999) Determination of N-carboxymethyllysine in milk products by a modified reversed phase HPLC method. Food Chem 65, 547-553.
23. Assar SH, Moloney C, Lim M, et al. (2009) Determination of N epsilon (carboxymethyl) lysine in food systems by ultra performance liquid chromatography-mass spectrometry. Amino Acids 36, 317-326.
24. Cai W, Gao Q-D, Zhu L, et al. (2002) Oxidative stress-inducing carbonyl compounds from common foods: novel mediators of cellular dysfunction. Mol Med 8, 337-346.
25. Vlassara H, Cai W, Crandall J, et al. (2002) Inflammatory mediators are induced by dietary glycotoxins, a major risk factor for diabetic angiopathy. Proc Natl Acad Sci 99, 15596-15602.
26. Sandu O, Song K, Cai W, et al. (2005) Insulin resistance and type 2 diabetes in high-fat fed mice are linked to high glycotoxin intake. Diabetes 54, 2314-2319.
27. Diamanti-Kandarakis E, Piperi C, Kalafoutis A, et al. (2005) Increased levels of serum advanced glycation end-products in women with polycystic ovarian syndrome. Clin Endocrinol 62, 37-43.
28. Negrean M, Stirban A, Stratmann B, et al. (2007) Effects of low and high advanced glycation endproduct meals on macro and microvascular endothelial function and oxidative stress in patients with type 2 diabetes mellitus. Am J Clin Nutr 85, 1236-1243.
29. Stirban A, Negrean M, Götting C, et al. (2008) Dietary advanced glycation endproducts and oxidative stress. Ann N Y Acad Sci 1126, 276-279.
30. Uribarri J, Negrean M, Sander D, et al. (2007) Single oral challenge by advanced glycation end products acutely impairs endothelial function in diabetic and non diabetic subjects. Diabetes Care 30, 2579-2582.
31. Vlassara H, Cai W, Goodman S, et al. (2009) Protection against loss of innate defenses in adulthood by low advanced glycation products (AGE) intake: role of the anti-inflammatory AGE receptor-1. J Clin Endocrinol Metab 94, 4483-4491.
32. Harcourt B, Sourris KC, Coughlan MT, et al. (2011) Targeted reduction of advanced glycation improves renal function in obesity. Kidney Int 80, 190-198.
33. Uribarri J, Cai W, Ramdas M, et al. (2011) Restriction of advanced glycation end products improves insulin resistance in type 2 diabetes: potential role of AGER1 and SIRT1. Diabetes Care 34, 1610-1616.
34. Tan KC, Chow WS, Tam S, et al. (2004) Association between acute-phase reactants and advanced glycation end products in type 2 diabetes. Diabetes Care 27, 223-228.
35. Stirban A, Negrean M, Stratmann B, et al. (2006) Benfotiamine prevents macro and microvascular endothelial dysfunction and oxidative stress following a meal rich in advanced glycation end products in individuals with type 2 diabetes. Diabetes Care 29, 2064-2071.
36. Poulsen MW, Bak MJ, Andersen JM, et al. (2014) Effect of dietary advanced glycation end products on postprandial appetite, inflammation, and endotehthelial activation in healthy, overweight adults. Eur J Nutr 53, 661-672.
37. Semba RD, Ang A, Talegawkar S, et al. (2012) Urinary carboxymethyl-lysine, a major advanced glycation end product in adults: The Energetics Study. Eur J Clin Nutr 66, 3-9.
38. Semba RD, Arab L, Sun K, et al. (2011) Fat mass is inversely associated with serum carboxymethyl-lysine, an advanced glycation end product, in adults. J Nutr 141, 1726-1730.
39. Ueda S, Yamagishi S, Matsui T, et al. (2011) Serum levels of advanced glycation end products (AGEs) are inversely associated with the number and migratory activity of circulating endothelial progenitor cells in apparently healthy subjects. Cardiovasc Ther 30, 249-254.
40. Tahara N, Yamagishi S, Takeuchi M, et al. (2012) Positive association between serum level of glyceraldehyde-derived advanced glycation end products and vascular inflammation evaluated by [18F] Fluorodeoxyglucose positron emission tomography. Diabetes Care 35, 2618-2625.
41. Luevano-Contreras C, Garay-Sevilla ME, Wrobel K, et al. (2013) Dietary advanced glycation end products diminishes inflammation markers and oxidative stress in patients with type 2 diabetes mellitus. J Clin Biochem Nutr 52, 22-26.
42. Semba RD, Gebauer SK, Baer DJ, et al. (2014) Dietary intake of advanced glycation end products did not affect endothelial function and inflammation in healthy adults in a randomized controlled trial. J Nutr 144, 1037-1042.
43. Diamanti-Kandarakis E, Piouka A, Livadas S, et al. (2009) Antimullerian hormone is associated with advanced glycosylated end products in lean women with polycystic ovary syndrome. Eur J Endocrinol 160, 847-53.
44. Yamagishi S, Adachi H, Nakamura K, et al. (2006) Positive association between serum levels of advanced glycation end products and the soluble form of receptor for advanced glycation end products in nondiabetic subjects. Metabolism 55, 1227-1231.
45. Davis KE, Prasad C, Vijayagopal P, et al. (2014) Serum soluble receptor for advanced glycation end products correlates inversely with measures of adiposity in young adults. Nutr Res 34, 478-485.
46. Selvin E, Halushka M, Rawlings AM, et al. (2013) sRAGE and risk of diabetes, cardiovascular disease and death. Diabetes 62, 2116-2121.
47. Giorgis T, D'Adamo E, Gianni C, et al. (2012) Could receptors for advanced glycation end products be considered cardiovascular risk markers in obese children? Antioxid Redox Signal 17, 187-191.
48. Vazzana N, Guagnana MT, Cuccurullo C, et al. (2012) Endogenous secretory RAGE in obese women: association with platelet activation and oxidative stress. J Clin Endocrinol Metab 97, E1726-E1730.
49. Norata GD, Garlaschelli K, Grigori L, et al. (2009) Circulating soluble receptor for advanced glycation end products is inversely associated with body mass index and waist/hip ratio in the general population. Nutr, Metab, Cardiovasc Dis 19, 129-134.
50. Koyama H, Shoji T, Yokoyama H, et al. (2005) Plasma level of endogenous secretory RAGE is associated with components of the metabolic syndrome and atherosclerosis. Arterioscler Thromb Vasc Biol 25, 2587-2593.
51. Ames J (2008) Determination of N-(carboxymethyl) lysine in foods and related systems. Ann N Y Acad Sci 1126, 20-24.
52. Mittelmaier S & Pischetsrieder M (2011) Multistep ultrahigh performance liquid chromatography/tandem mass spectrometry analysis for untargeted quantification of glycating activity and identification of most relevant glycation products. Anal Chem 83, 9660-9668.
53. Tessier FJ & Birlouez-Aragon I (2012) Health effects of dietary Maillard reaction products: The results of ICARE and other studies. Amino Acids 42, 1119-1131.
54. Hanssen NMJ, Engelen L, Ferreira I, et al. (2013) Plasma levels of advanced glycation endproducts Nε-(carboxymethyl)lysine, Nε(carboxyethyl)lysine, and pentosidine are not independently associated with cardiovascular disease in individuals with or without type 2 diabetes: The Hoorn and CODAM studies. J Clin Endocrinol Metab 98, E1369-E1373.
55. Piroddi M, Palazzetti I, Quintaliani G, et al. (2011) Circulating levels and dietary intake of the advanced glycation end product marker CML in chronic kidney disease patients on a conservative predialysis therapy: A pilot study. J Ren Nutr 21, 329-339.
56. Birlouez-Aragon I, Saavedra G, Tessier FJ, etal. (2010) A diet based on high-heat-treated foods promotes risk factors for diabetes mellitus and cardiovascular diseases. Am J Clin Nutr 91, 1220-1226.
57. Wu CH, Huang SM, Lin J-A, et al. (2011) Inhibition of advanced glycation endproduct formation by foodstuffs. Food Funct 2, 224-234.
58. Pepys MB & Hirschfield GM (2003) C-reactive protein: A critical update. J Clin Invest 111, 1805-1812.
59. Ramasamy R, Vannucci SJ, Yan SSD, et al. (2005) Advanced glycation end products and RAGE: A common thread in aging, diabetes, neurodegeneration and inflammation. Glycobiology 15, 16R-28R.